Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
| Autor: | Mehmet Onur Omaygenç, Bilal Boztosun, Hacı Murat Güneş, Beytullah Çakal, Ozgur Ulas Ozcan, Filiz Kizilirmak Yilmaz, Sinem Çakal, Oguz Karaca, Arzu Yıldırım |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment 0206 medical engineering 02 engineering and technology Coronary Artery Disease Revascularization Lesion Coronary artery disease Percutaneous Coronary Intervention Internal medicine medicine Myocardial infarction Adverse effect Bioresorbable Scaffolds Original Paper Everolimus business.industry digestive oral and skin physiology Percutaneous coronary intervention 021001 nanoscience & nanotechnology medicine.disease 020601 biomedical engineering Cardiology Medicine medicine.symptom 0210 nano-technology Cardiology and Cardiovascular Medicine business Mace medicine.drug |
| Zdroj: | Postępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology Advances in Interventional Cardiology, Vol 16, Iss 4, Pp 391-398 (2020) |
| Popis: | Introduction: Elevated risk of adverse events in comparison to metallic stents resulted in withdrawal of everolimus-eluting bioresorbable scaffolds (eBVS), known as the most intensively studied BVS. There is a paucity of data comparing the two different BVS. Aim: To evaluate the long-term clinical outcomes of the novolimus-eluting bioresorbable vascular scaffold (nBVS) compared with eBVS. Material and methods: Consecutive patients treated with nBVS or eBVS in our center were screened. The primary outcome was the 3-year rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and target-lesion revascularization (TLR). Results: After matching, 98 patients treated with 135 eBVS were compared with 98 patients treated with 136 nBVS. Baseline characteristics, clinical presentation, and lesion characteristics were comparable in both groups. The 3-year MACE rate was higher in the eBVS group (17.3% vs. 6.1%; p log-rank = 0.02). The occurrence of TLR (16.3% vs. 5.1%; p log-rank = 0.02) and TV-MI (8.2% vs. 0 %; p log-rank = 0.004) was also higher in the eBVS group except for cardiac deaths (1% vs. 2%; p log-rank = 0.98, eBVS vs. nBVS, respectively). Of note, definite device thrombosis rate was markedly increased in the eBVS group (5.1% vs. 0%; p log-rank = 0.03). Conclusions: The present study revealed that the 3-year event risk was lower for nBVS compared to eBVS. More evidence is needed to evaluate long-term performance of novolimus-eluting biovascular platforms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|